ACM
MDGL icon

ADAR1 Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

ADAR1 Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-500
Closed -$116K – 278
2023
Q4 		$116K Buy
+500
New +$87.5K 0.04% 92

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ADAR1 Capital Management's MDGL Position: Q1 2026 in Review

ADAR1 Capital Management held its Madrigal Pharmaceuticals (MDGL) position steady in Q1 2026 at 895 shares worth $469K. The position accounts for 0.03% of the portfolio, ranked #208.

ADAR1 Capital Management first reported a position in MDGL in Q3 2024 and has held it in 6 quarters since. The position peaked at $2.25M in Q3 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • ADAR1 Capital Management held 895 shares of Madrigal Pharmaceuticals worth $469K as of Q1 2026.
  • ADAR1 Capital Management left its Madrigal Pharmaceuticals share count unchanged in Q1 2026.
  • Madrigal Pharmaceuticals made up 0.03% of ADAR1 Capital Management's portfolio in Q1 2026, its #208 holding.
  • ADAR1 Capital Management first reported a position in Madrigal Pharmaceuticals in Q3 2024 and has held it in 6 quarters since.
  • ADAR1 Capital Management's Madrigal Pharmaceuticals position peaked at $2.25M in Q3 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.